Recent Updates
Recently added Catalysts
HYPR Positive Sentiment

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Hyperfine, Inc. reported preliminary third-quarter revenue of about $6.0 million, showcasing strong commercial performance. The company also reaffirmed its full-year revenue outlook for 2026, estimating between $20 to $22 million. This growth is attributed to the effective implementation of its commercial strategy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Record preliminary revenue of approximately $6.0 million.
  • Reaffirmation of full year 2026 revenue outlook of $20 to $22 million.
  • Successful execution of commercial strategy driving growth.

Full Press Release Details

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited revenue, net cash burn, and cash and cash equivalents for the third quarter ended September 30, 2026. “Our preliminary third-quarter results demonstrate that execution of our commercial strategy is driving meaningful growth. M

Frequently Asked Questions

What was Hyperfine's preliminary Q3 revenue?

Hyperfine reported a preliminary third-quarter revenue of approximately $6.0 million.

What is Hyperfine's revenue outlook for 2026?

The company reaffirmed its full-year 2026 revenue outlook of $20 to $22 million.

What drives Hyperfine's revenue growth?

The growth is driven by the effective execution of Hyperfine's commercial strategy.

ShareAdd on Google
Tags: HYPR Hyperfine MRI system revenue growth 2026 outlook
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$43M liquidity · $2M/mo burn
~16 mo
Low dilution risk